Retatrutide’s side effects are well documented in clinical trials, and most are dose-related.
Gastrointestinal effects
Common and dose-related side effects are the main reason patients discontinue. In the Phase II obesity trial, nausea reached 60% in the highest dose group versus 11% for placebo. Vomiting was 26% versus 1%. Diarrhea was 20%, and constipation was 16%. Discontinuation due to side effects ranged from 6% to 16% in retatrutide groups versus zero for placebo.
Heart rate
Heart rate increased in a dose-dependent manner, peaking around week 24 and declining by week 48. Overall, 6% of participants experienced a composite of arrhythmias and conduction disorders, reaching 14% in one dose group. Because both GLP-1 and glucagon receptor activity can increase heart rate, this finding is most likely related to the glucagon arm. However, a 48-week trial with 338 participants is limited in its ability to fully characterize this finding.
Skin sensitivity
This is an uncommon side effect seen only with this compound. Seven percent of participants treated with retatrutide reported skin hypersensitivity and sensitivity reactions, versus 1% for placebo. All cases were non-serious, none had visible skin lesions, and none led to discontinuation. No clear mechanism has been identified. If you are taking the drug and notice unusual skin sensations, this may be the reason.
Pancreas, gallbladder, and liver
One serious case of acute pancreatitis occurred in the 12 mg group, and three biliary events occurred in the Phase II obesity trial. Because of the small trial size, these events can neither confirm nor exclude a class effect. One percent of participants had transient liver enzyme elevations more than three times normal, and mean liver enzyme levels remained unchanged or decreased at 48 weeks.
Conclusion
Retatrutide’s side effect profile is clear and dose-related. Understanding these data helps make more rational judgments when using or evaluating the drug.